Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06059521
Recruiting Not applicable

Software Refraction With Mobilerone Versus Retinoscopy

NCT06059521 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Airdoc Technology Co., Ltd
Phase
Not applicable
Started
2023-07-15
Last updated
2023-09-28

Condition(s) studied

MyopiaMyopia, ModerateAstigmatism

Investigational drug(s) / intervention(s)

Software refraction with Eye Test Technology in a mobileroneRetinoscopy

Software refraction with Eye Test Technology in a mobilerone: Refraction is done by software App by a mobilerone software installed.

Retinoscopy: Retinoscopy is an objective refraction method with retinoscope.

Study summary

Software refraction in the mobilerone for myopia and astigmatism is a novel medical device for myopia adults and elder children with or without astigmatism. And the investigators would like to test its accuracy and efficacy as well as safety.

Eligibility

Sex
ALL
Min age
10 Years
Max age
46 Years
Healthy volunteers
Accepted
Inclusion Criteria: * • subject with ametropia on each eye ≤-12.00D * subject with best corrected visual acuity ≥ 20/25, no amblyopia * subject with normal transparency of eyes * subject with a healthy fundus that does not reveal major abnormalities that may affect vision due to the fluctuate situations * subject able to cooperate with the screen and the operator * subject without heavy drug treatment that may affect vision as synthetic antimalarials, corticosteroids * non-diabetic subject * non nystagmus subject * non-strabismus subject * subject who has not had eye surgery less than 1 year old Exclusion Criteria: * • subject with a topography showing an anomaly (keratoconus type or other) * subject with hyperopia or presbyopia * subject with mild myopia ≥ -1.00D * subject who cannot speak with the operator including those staff of local optometrists or ophthalmologists

Primary outcome measure(s)

  • Spherical Equivalence(D) — 1-day and within 2 weeks
    Spherical is myopic equivalence with total spherical plus half the cylinder diopter.
  • Astigmatism Power(D) — 1-day and within 2 weeks
    Cylinder value of each total astigmatism power
  • Astigmatism axial — 1-day and within 2 weeks
    Cylinder axis of astigmatism
  • pupil distance (mm) — 1-day and within 2 weeks
    pupil distance measurement with software or autorefractor

Trial sites (3)

FacilityCityRegionStatus
Airdoc MPC Opthalmology Clinics Beijing Beijing Municipality Not Yet Recruiting
Jenny QIU Beijing Beijing Municipality Recruiting
Qiu Jenny Beijing Haidian District Recruiting

More Beijing Airdoc Technology Co., Ltd. trials in China

Myopia Control Combined PBM With Myopic Defocus Lens in Children Recruiting
Myopia Preventing With Distance-image Screen Recruiting
Sustained Effect of Red-light Therapy for Myopia Control: A 2-Year Post-Trial Follow-up Study Active, not recruiting

Other trials for the same condition

Multicenter RCT: LED Red Light Dose-Response in Myopia Progression Control Starting soon
Assessment of DOT Spectacles in Chinese Children Extension Recruiting
Comparison of Two Rotational Alignment Methods for Astigmatism Correction in SMILE Surgery Starting soon
The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens Active, not recruiting
Managing Premyopia in Chinese Children Using Artificial Intelligence Assisted Defocus Incorporated Multiple Segments Based Spectacle Lens: a Randomized Controlled Clinical Trial Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06059521 on ClinicalTrials.gov ↗ ← All trials in China